A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

NCT02829723 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: BLZ945
DRUG: PDR001

Sponsor

Novartis Pharmaceuticals